skip to Main Content

FDA lifts clinical hold on trial of CAR-T for metastatic pancreatic, prostate

Newsfeed image, light gray text on dark gray background
The FDA lifted its clinical hold on a study evaluating BPX-601 and rimiducid for patients with previously treated metastatic pancreatic or prostate cancers, according to a press release from the agent’s manufacturer.

BPX-601 (Bellicum Pharmaceuticals) is an autologous chimeric antigen receptor T-cell therapy that targets tumor cells expressing high levels of prostate stem cell antigen (PSCA). Read more . . . 


Back To Top